Degron Therapeutics

Degron Therapeutics

Degron Therapeutics

  • AI assistants read this profile 31 times in 14 days

Clinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines.

2020Active24San Diego, USA
Rate

About

Degron Therapeutics develops novel molecular glue degrader (MGD) drugs using its proprietary GlueXplorer® platform to target historically intractable disease targets. This platform leverages a large, structurally differentiated compound library and advanced screening systems to address the challenges of rational MGD design. The company aims to "drug the undruggable" by creating new therapeutic options for diseases.

Signals agent

Reach companies that have budget right now

Every week the agent finds companies in your market that just got money or started hiring to spend it, and the person to talk to. You choose who to reach; nothing is sent for you.

  • Just raised a roundFresh budget, the week it lands
  • Hiring sales and marketingGo-to-market roles mean money to spend
  • Hiring fastA jump in open roles across the company
  • In the newsLaunches and announcements worth a message
  • The decision makerWho to contact, with a message you can edit

Is your startup an alternative to Degron Therapeutics?

People comparing tools land here. Get listed beside these.

Copy Degron Therapeutics's SEO strategy

How often they publish, which searches their posts chase and their newest posts. Then outrank them.

All funding rounds

Key facts

Website
degrontx.com
Headquarters
San Diego, California, USA
Founded
2020
Founder
Stuart L. Schreiber
Employees
24
Total funding
$40M (Series A Extension)
Business model
B2B

Funding rounds

Funding rounds raised by Degron Therapeutics
DateRoundAmountLead investors
14 May 2026Series A Extension$40MLAPAM CAPITAL

Benchmarking

See how your site ranks against 16,849 startups

Degron Therapeutics sits in the 32nd percentile for Domain Rating. Check where yours lands, free.

Degron Therapeutics has a Domain Rating of 25, the 32nd percentile of 16,849 startups we track.

Scores

Measured, not editorial

25

Measured by AhrefsAhrefs DR

Strength of the site’s backlink profile, on Ahrefs’ 0-100 Domain Rating scale. Licensed third-party data, not our opinion.

Below median

Check yours
27

Measured by StartupHub.aiAgent Readiness

How well an AI agent can read and use this site: structured data, clean markup, and whether key facts are reachable without running JavaScript. We scan the live site.

Bottom 25%

Scan yours
59

Measured by Google PageSpeedSite Speed

Google PageSpeed mobile performance for the company’s own site. Measured by Google, not by us.

Below median

PageSpeed
57

Measured by StartupHub.aiData Trust

Whether this company is a safe place to put your data: security posture, privacy signals, and reputation evidence we could verify.

Below median

Measured by StartupHub.aiSecurity

What this company’s API or MCP server gives an anonymous stranger: transport, whether anything answers without credentials, CORS, response headers and, when an MCP server replies, which of its tools can be called with no key. Scanned live, on request, because a security verdict months old is worse than none.

Click to scan

Agent Readiness

Can AI agents use your site?

Degron Therapeutics scores 27. Check yours free in a few seconds, or let Max Agent rerun it daily.

Run it daily with Max Agent
Median 41Across 23,755 scanned sites

Get notified when Degron Therapeutics changes

Used Degron Therapeutics? Write a review and get $5 in credits

Your first review on StartupHub.ai adds 1,250 credits to your account. Spend them on:

  • Email finder
  • Market Map Maker
  • Agent Readiness scans
  • Deep intel
  • Tech stack scans

Frequently asked

Is Degron Therapeutics growing?

Yes, fast. Our data shows it raised $40M in a Series A Extension in May 2026.

Who owns Degron Therapeutics?

Degron Therapeutics is privately held, owned by its founders and investors. Investors on record include LAPAM CAPITAL, GTJA Investment Group, Fortune Capital and CSPC & Growth. Exact stakes are not public.

Are there companies like Degron Therapeutics?

Yes. We list 6 companies like Degron Therapeutics, including Moderna, Epicrispr Biotechnologies and Pixelgen Technologies.

Is Degron Therapeutics trustworthy and reputable?

StartupHub's Data Trust & Reputation score for Degron Therapeutics is 57 out of 100, a use-caution rating, based on site security posture, privacy practices, malware and phishing checks, and public reputation signals.

How much funding has Degron Therapeutics raised?

Degron Therapeutics has raised a total of $40M in funding. The most recent round on record is Series A Extension.

How many employees does Degron Therapeutics have?

Degron Therapeutics has approximately 24 people on record.

SEC filings, insider activity, nonprofit links and pay benchmarks for Degron Therapeutics:

Company details: from public sources. Funding: 1 round on file. Ownership: not yet claimed by the company. Scores: measured by named tools; each links to its method. Our rules

Categories

Need more than this profile? Deep intel researches any company website: team, funding, customers and tech.

Max Agent

Let Max Agent watch Degron Therapeutics and its market for you

New competitors, funding rounds, pricing and product changes, and where you show up in AI answers, in one weekly report.

Free week

Starter listings, once

AI answers checked

Daily for 7 days

  • ChatGPT
  • Perplexity

Max Agent

$79 a month, or $9.99 with our badge on your site

AI answers checked

Every week

  • ChatGPT
  • Claude
  • Perplexity
  • Gemini